Compare Citius Pharmaceuticals Inc (CTXR) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Mongodb Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Mongodb Inc trades at $370.72 (market cap $29.24B). The key difference: Mongodb Inc is far larger — about 2120.4× Citius Pharmaceuticals Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Mongodb Inc for 45 Days on average.
| CTXR | MDB | |
|---|---|---|
Market Cap | $13.79M | $29.24B |
Volume | 156,684 | 1,304,995 |
Sector | Health | Technology |
52-Week High | $1.82 | $472.29 |
52-Week Low | $0.48 | $225.95 |
Typical Hold Time | 16 Days | 45 Days |
Enterprise Value | $3.96M | $26.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
MongoDB (MDB) trades at $371.35, up 2.95% today, showing strong momentum despite recent volatility. The stock faces bearish technical signals with resistance at $373, while fundamentals reveal impressive revenue growth from $1.7B to $2.0B in 2025, though net losses persist. Recent investor day highlighted AI product launches and raised long-term targets, but CEO transition creates uncertainty. Analyst consensus remains strongly bullish with $457 price target.
MDB presents a growth-at-a-price scenario with premium valuations (P/E 511) offset by strong revenue momentum and AI positioning. Near-term risks include leadership transition execution and competitive pressures, while the 80% buy rating suggests Wall Street sees 23% upside potential. Investors must weigh expensive multiples against transformative AI opportunities in database market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
